Molecular Mechanisms of Drug Resistance and Metastasis

A ‘one-two punch’ against aggressive breast cancer: Targeting a LOX-mitochondria-ferroptosis vulnerability in TNBC

Our latest study, published in Cell Reports Medicine, uncovers an unexpected intracellular role for lysyl oxidase (LOX), traditionally known as an extracellular matrix regulator, in maintaining mitochondrial homeostasis and protecting triple-negative breast cancer (TNBC) cells from ferroptosis. Pharmacological inhibition of LOX with our best-in-class inhibitor, LXG6403, disrupts mitochondrial homeostasis and weakens ferroptosis defense mechanisms. As the cancer cells adapt, they become increasingly dependent on the backup DHODH pathway, creating a vulnerability that can be targeted with Read more

By sahinozgur, ago

Congratulations to Dr. Sahin on his new role as Program Director of Science Translation for the Hollings Advisory for Rapid Translation (HART).

Our PI, Dr. Ozgur Sahin, has accepted the position of Program Director of Science Translation for the Hollings Advisory for Rapid Translation (HART). In this newly created role, he will lead and support strategic initiatives to advance the translation of basic science into investigator-initiated clinical research. We sincerely congratulate him on this achievement!

By sahinozgur, ago

Two posters in AACR 2025

Kubra presented a poster entitled “Targeting TACC3 inhibits metastasis in breast cancer with centrosome amplification“. Ozge presented a poster entitled “LINC00152-regulated PDE4D mediates drug resistance and metastasis in highly aggressive breast cancer“.

By sahinozgur, ago